May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% at Trough Drug Effects in a Rabbit Model
Author Affiliations & Notes
  • H. P. Sandoval
    Ophthalmology, Magill Research Center Institute - MUSC, Charleston, South Carolina
  • L. Fernández de Castro
    Ophthalmology, Magill Research Center Institute - MUSC, Charleston, South Carolina
  • D. Waterbury
    Raven Biosolutions LLC, San Carlos, California
  • K. Solomon
    Ophthalmology, Magill Research Center Institute - MUSC, Charleston, South Carolina
  • Footnotes
    Commercial Relationships  H.P. Sandoval, None; L. Fernández de Castro, None; D. Waterbury, None; K. Solomon, None.
  • Footnotes
    Support  unrestricted educational grant from Allergan
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. P. Sandoval, L. Fernández de Castro, D. Waterbury, K. Solomon; PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% at Trough Drug Effects in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5677.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the ability of ketorolac 0.4% and bromfenac 0.09% to inhibit PGE2 at trough drug effect following cataract surgery in a rabbit model.

Methods: : Twenty-nine New Zealand White rabbits of the same age and weight (7-9 lbs) were randomized to receive either ketorolac four-times daily (n=10) or bromfenac twice-daily (n=10) in the operative (right eye) commencing 1-day prior to cataract surgery. An additional 9 rabbits did not receive pre-operative dosing with an NSAID and served as controls. Post-operatively, the rabbits continued to receive ketrolac at four-times daily and bromfenac at 2-times daily dosing. On post-operative day 1, aqueous humor was obtained via a paracentesis from the operative eyes 4-6 hours following the last dose of ketorolac and 8-12 hours following the last dose of bromfenac. PGE2 levels were determined based on the aqueous samples using an ELISA immunoassay.

Results: : Ketorolac 0.4% inhibited PGE2 to a statistically greater extent than did bromfenac at trough drug effect. Mean PGE2 levels were 323.5 + 132.5 pg/mL with ketorolac and 507.8 + 185.5 pg/mL with bromfenac (P=.025). Both NSAIDs controlled PGE2 to a statistically significantly greater extent than did untreated control (mean of 6112.8 + 4879.6 pg/mL, P≤.003).

Conclusions: : At trough drug levels, ketorolac inhibited PGE2 to a significantly greater extent than did bromfenac in a rabbit cataract surgery model.

Keywords: cataract • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • aqueous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×